Characteristics and risk factors of immune-related adverse events in patients receiving immune checkpoint inhibitor combination therapy - Top-Institutions - MDSpire

Characteristics and risk factors of immune-related adverse events in patients receiving immune checkpoint inhibitor combination therapy

  • By

  • Yao Qiu

  • Xincai Zhao

  • Juan Chen

  • Manman Zhang

  • Yonggang Wang

  • Cheng Guo

  • Jianping Zhang

  • Rong Xu

  • May 29, 2026

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Oncology

  • #2

    National Cancer Institute
    National Cancer Institute

    Bethesda, Maryland

    Key Differentiators

    • Oncology

  • #3

    Mass General Cancer Center
    Mass General Cancer Center

    Boston, Massachusetts

    Key Differentiators

    • Oncology

  • #4

    Mass General Brigham
    Mass General Brigham

    Boston, Massachusetts

    Key Differentiators

    • Oncology

  • #5

    Rockefeller University
    Rockefeller University

    New York, New York

    Key Differentiators

    • Oncology

Original Source(s)

Characteristics and risk factors of immune-related adverse events in patients receiving immune checkpoint inhibitor combination therapy

  • by Yao Qiu, Xincai Zhao, Juan Chen, Manman Zhang, Yonggang Wang, Cheng Guo, Jianping Zhang, Rong Xu

  • May 29, 2026

Related Content

Why We Made a Mobile Digital Pathology Lab

Todd R. Minnigh and his team created ScanVan to address a problem with rare cancer diagnosis that had a particularly personal significance

Could One Test Replace Multiple Leukemia Assays?

Researchers assess whether long-read transcriptome sequencing can streamline B-ALL diagnostics

  • May 29, 2026

  • 3 min
Preclinical Study in Mice Addresses a Question: Should RAS Inhibitors Be Given Preemptively?

With recent data that RAS inhibition can improve survival in metastatic pancreatic cancer, the optimization of these agents has become a research priority. Minh Than, MD, PhD, a clinical and research ...